Germline testing is also recommended for patients with pathogenic/likely pathogenic BRCA2 mutations identified through tumor sequencing and should also be considered in patients with alterations in other genes linked to cancer predisposition syndromes (i.e., BRCA1, ATM, MMR genes). The gene discussed is BRCA2; the disease is neoplasm.